In conclusion, our findings establish a mechanistic framework for ARL3‐dependent oncogenesis in HR+ breast cancer, highlighting its potential as both a biomarker of endocrine resistance and a druggable target for innovative therapeutic strategies. Here, ARL3 is linked to breast carcinoma.